<DOC>
	<DOCNO>NCT02405039</DOCNO>
	<brief_summary>This randomize , double mask study design evaluate safety EBI-005 5 mg/mL topical ophthalmic solution give three time daily ( TID ) compare vehicle-control one year period subject dry eye disease ( DED ) . Approximately 188 subject enrol either EBI-005 vehicle 15 center United States ( US ) Canada .</brief_summary>
	<brief_title>Study EBI-005 Dry Eye Disease ( DED )</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Key 1 . Have history dry eye disease ( DED ) eye support previous clinical diagnosis selfreported history subjective complaint least 6 month prior Visit 1 2 . Are willing able follow instruction present require study visit duration study Key 1 . Have ocular condition could confound study assessment ( ocular infection , herpetic neurotrophic keratitis , StevenJohnson Syndrome , etc ) 2 . Have penetrate intraocular surgery within 12 month prior Visit 1 3 . Be unwilling comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>DED</keyword>
	<keyword>Disease</keyword>
</DOC>